Navigation Links
Isis Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
Date:11/24/2009

CARLSBAD, Calif., Nov. 24 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at Piper Jaffray's 21st Annual Health Care Conference on Tuesday, December 1, 2009, at 10:30 a.m. ET at The New York Palace Hotel.

A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com. A replay of the presentation will be available on the Isis Web site within 48 hours and will be archived for a limited time.

About Isis Pharmaceuticals, Inc.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 19 drugs in development. Isis' drug development programs are focused on treating cardiovascular, metabolic and severe neurodegenerative diseases and cancer. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics. Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,600 issued patents worldwide. Additional information about Isis is available at www.isispharm.com.

SOURCE Isis Pharmaceuticals, Inc.


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... HILLS, Calif. , June 20, 2017 SkylineDx ... the use of MMprofiler with SKY92, the company,s prognostic ... In a poster presentation at the 22 nd ... Madrid, Spain , SkylineDx researchers will demonstrate ... patients. In a separate e-poster presentation ...
(Date:6/16/2017)... 2017  Exactly 50 years ago today, the Monterey Pop ... known as the San Francisco "Summer of Love."  To celebrate ... radical innovations in strategic market research portals that it will ... beginning of Northern Light,s "Summer of Love (For Our Customers)."  ... ...
(Date:6/13/2017)... Ind. , June 13, 2017 Zimmer Biomet ... musculoskeletal healthcare, today announced that the U.S. Food and Drug ... dated June 3, 2015 relating to its Zhejiang, ... "The successful clearance of the ... manufacturing facility is a measure of the progress ...
Breaking Medicine Technology:
(Date:6/26/2017)... ... 26, 2017 , ... If the devil is in the ... these days. According to recent estimates, 75 – 80% of the medical bills ... studies point to Electronic Health Records (EHR) with automated features designed to ease ...
(Date:6/25/2017)... ... 2017 , ... Create a feel-good lyric music video in Final Cut Pro X with ProLyric ... and write in the lyrics to any song. ProLyric flies in the text for each ... text can be added modularly for optimal control. ProLyric makes editing any music video or ...
(Date:6/25/2017)... (PRWEB) , ... June 25, 2017 , ... With a heatwave currently bearing down on ... hanging out at the pool. Being swimsuit ready is easy with laser hair removal. ... repeat again can be a burdensome routine when all you want to do is get ...
(Date:6/24/2017)... ... June 24, 2017 , ... Dr. Mitchell Mehlman and ... in Lake Ronkonkoma, Dental365 offers patients high-quality and affordable routine and emergency dental ... dentist fit into their patients’ busy lifestyles. Dental365 also gladly work with most ...
(Date:6/23/2017)... ... 23, 2017 , ... "The Better Care Reconciliation Act (BCRA) ... to people with all chronic conditions, including mental illnesses, while increasing the cost ... Affordable Care Act (ACA) requirement that insurers cover pre-existing conditions, it does not ...
Breaking Medicine News(10 mins):